Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQT Study of Eliapixant in Healthy Participants
NCT04423744Phase 1Completed
- Sponsor
- Bayer
- Start
- Jun 2020
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of eliapixant in chronic cough, endometriosis and overactive bladder (OAB) (4 arms), sponsored by Bayer. Primary endpoint: Time-matched, placebo-corrected change from baseline of the individually corrected QT interval (QTcI) at Day 3. Started Jun 2020; status: completed.
02
Drugs
eliapixant
03
Conditions
chronic coughendometriosisoveractive bladder (OAB)
Beyond the preview
Go deeper on NCT04423744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04423744.